BPC-157 is a synthetic peptide promoted for tendon, ligament, muscle, joint, and digestive-tract recovery, but human evidence is very limited. Most findings come from animal and laboratory studies 1. It is not FDA-approved for any condition, has no established evidence-based dose, and should not be used without qualified medical guidance 4.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →What is BPC-157?
BPC-157 is short for Body Protection Compound-157. It is also called a gastric pentadecapeptide because it contains 15 amino acids and was developed from research on protective protein fragments found in gastric juice 1.
What BPC stands for
“BPC” means Body Protection Compound. The “157” refers to the peptide’s 15-amino-acid sequence. In plain English, it is a short chain of amino acids studied as a signaling molecule, not a vitamin, mineral, hormone, or approved drug 1.
Why it is called a peptide
A peptide is a short chain of amino acids. Proteins are longer chains. Many natural peptides act like messengers in the body, helping cells communicate about growth, inflammation, blood flow, or repair 1.
How synthetic BPC-157 differs from natural body peptides
Synthetic BPC-157 is made in a lab. That matters because purity, sterility, and exact composition depend on the manufacturer. Products sold as “research peptides” can vary, and the FDA warns that buying medicines from unsafe online sources can expose patients to contaminated, counterfeit, or poor-quality products 8.
What are the quick facts about BPC-157?
BPC-157 has 1 main problem for patients: the online claims are far ahead of the human evidence. The most useful way to think about it is by separating proposed uses, evidence level, FDA status, and safety gaps.
| Question | What patients should know |
|---|---|
| FDA approval status | BPC-157 is not FDA-approved for any medical condition, and no FDA-approved brand name is identified in the supplied evidence 4. |
| Main claimed uses | Online claims focus on tendon, ligament, muscle, bone, joint, and digestive-tract recovery, but these are investigational claims 1. |
| Strength of human evidence | A 2025 systematic review found 36 included studies: 35 preclinical studies and 1 clinical study 1. |
| Sports-ban status | BPC-157 may be prohibited in sport; athletes should check WADA and their own league rules 6. |
| Key safety unknowns | There is no broad long-term human safety profile, and product-quality risks are a major concern 1. |
What do people use BPC-157 for?
BPC-157 is most often promoted for soft-tissue recovery within days to months, but that timeline is not evidence-based for patients. The common claims come from animal studies, lab studies, athlete discussions, and small human reports—not large randomized human trials 1.
Tendon, ligament, and muscle recovery claims
In orthopedics and sports medicine, BPC-157 is discussed for tendon injury, ligament injury, muscle injury, and bone injury models. A systematic review reported improved functional, structural, and biomechanical outcomes in preclinical models, but these were mainly animal studies 1.
Joint pain and knee-pain claims
The limited human musculoskeletal evidence includes a small retrospective knee-pain report. In that report, 7 of 12 patients reported relief lasting more than 6 months after intra-articular BPC-157, but the study design was small, non-randomized, and not enough to prove benefit 1. Individual results vary.
Digestive-tract and gut-lining claims
BPC-157 is linked to digestive-tract mucosal integrity because it was developed from gastric peptide research. Animal and lab studies have explored gut-protection pathways, but this does not establish that BPC-157 improves gut symptoms or digestive disease in humans 1.
Inflammation and tissue-protection claims
Preclinical work suggests BPC-157 may affect inflammatory cytokines and nitric oxide signaling. These mechanisms are biologically interesting, but mechanism studies do not prove that a treatment is safe or effective for a real patient 1.
What does the research actually show?
BPC-157 research is mostly preclinical: 35 of 36 studies in a 2025 review were animal or lab studies. That means the signal is worth studying, but it is not the same as proven human benefit 1.
| Evidence level | What it can tell us | What it cannot prove |
|---|---|---|
| Cell or lab research | Possible pathways, such as angiogenesis, fibroblast activity, cytokines, and nitric oxide signaling 1 | Whether a person will heal faster or feel better |
| Animal studies | How BPC-157 behaves in injury models of muscle, tendon, ligament, and bone 1 | Human effectiveness, best route, long-term safety, or ideal patient selection |
| Small human observational report | A signal that some people with knee pain reported relief after treatment 1 | Cause and effect, placebo-adjusted benefit, durability, or safety |
| Large randomized human trials | This would be the kind of evidence needed to estimate real benefit and risk | Not available for BPC-157 based on the supplied evidence 1 |
Animal and lab evidence for musculoskeletal healing
Animal models reviewed in 2025 suggest BPC-157 may influence muscle, tendon, ligament, and bone healing. The same review also noted pathway findings related to cell growth and angiogenesis, which means new blood-vessel growth 1.
The small human knee-pain study and its limits
The human evidence is thin. The cited knee-pain report was retrospective, included 12 people, and did not include the kind of randomized placebo comparison that helps separate drug effect from natural recovery, expectation, rehab, or other treatments 1.
Why animal findings do not prove human benefit
Animal studies can show whether a compound is worth studying. They cannot prove that a peptide helps human injuries, digestive symptoms, or pain. Differences in species, injury type, dose exposure, route, and follow-up can change results 1.
What is still unknown about effectiveness
We still do not have strong human answers on who might benefit, which condition to study, what outcomes matter, how long effects last, or how BPC-157 compares with standard care such as rehab, time, nutrition, sleep, and approved medical treatments 1.
How might BPC-157 work in the body?
BPC-157 is being studied for several repair-related pathways, but none of these pathways proves a clinical benefit. Think of mechanisms as clues, not outcomes.
Angiogenesis and blood-vessel signaling
Angiogenesis means forming new blood vessels. Preclinical studies suggest BPC-157 may interact with blood-vessel signaling, which could matter in tissue repair models, but this has not been proven to improve healing in well-controlled human trials 1.
Fibroblast activity and collagen-related repair
Fibroblasts are cells that help build the structure around tissues, including collagen-rich repair tissue. BPC-157 has been investigated in models involving fibroblast activity and collagen organization, but the clinical meaning in people is still uncertain 1.
Growth-hormone receptor expression
The systematic review reported that studies suggest BPC-157 may enhance growth hormone receptor expression. That does not mean it works like growth hormone or that it improves strength, recovery, or body composition in humans 1.
Inflammatory cytokines and nitric-oxide pathways
Inflammatory cytokines are immune signals. Nitric oxide helps regulate blood-vessel tone and blood flow. BPC-157 has been investigated in these pathways, but human safety and effectiveness are not established 1.
Is BPC-157 FDA-approved or legally compounded?
BPC-157 has no FDA-approved indication in the United States as of August 2026. The FDA’s public drug databases are the right place to verify whether a drug has an approved application, label, or brand-name product 4.
No approved indication in the United States
No FDA-approved brand name, generic name, or established FDA-approved use was identified for BPC-157 in the supplied evidence. That means claims about treating tendon tears, arthritis, gut problems, or pain should be viewed as investigational 1, 4.
Why regulatory status matters for patients
Regulatory status matters because FDA approval includes review of manufacturing, labeling, clinical evidence, and safety data for a specific use. A peptide can be popular online while still lacking this type of review 4, 7.
Quality, sterility, and contamination concerns with unregulated peptides
The main safety divide is licensed versus unlicensed. A licensed provider and a state-licensed 503A pharmacy create oversight around patient screening, prescription review, and dispensing. “Research chemical” vendors do not provide the same medical guardrails, and FDA’s BeSafeRx program warns patients about unsafe online drug sources 8.
Is BPC-157 safe to take every day?
BPC-157 does not have an established daily-use safety profile in humans. There is also no evidence-based human dose in the supplied evidence, so online protocols should not be treated as medical guidance 1.
Why there is no established daily-use safety profile
To understand daily safety, researchers need human studies that track adverse events, lab markers, medication interactions, duration of use, and longer follow-up. The 2025 systematic review reported a lack of clinical safety data for BPC-157 1.
What preclinical safety data can and cannot tell us
Animal studies reviewed reported no adverse effects across several organ systems, but animal safety findings cannot be treated as proof of human safety. Human immune responses, disease states, medications, and product quality can change risk 1.
Why long-term human safety remains unknown
Long-term safety is especially important for compounds promoted for daily or repeated use. For BPC-157, we do not have strong human data on months-to-years exposure, cancer-related safety signals, fertility, pregnancy, autoimmune conditions, kidney disease, or liver disease 1.
What are the possible side effects or risks of BPC-157?
BPC-157 risk is hard to estimate because human safety data are sparse. The risks patients should think about include unknown drug effects, injection complications, product quality, and sports eligibility.
Known evidence gaps in humans
A key risk is uncertainty. Without larger human trials, we do not know the true rate of side effects, which patients should avoid it, or whether BPC-157 interacts with common medications or medical conditions 1.
Injection-related risks
Any injection can cause pain, bruising, bleeding, irritation, infection, or sterile abscess if technique or sterility is poor. These risks are higher when a product is obtained outside a licensed medical and pharmacy system 7, 8.
Product-quality and contamination risks
The 2025 review warned about unregulated manufacturing, contamination, and unknown human safety. This is why we caution patients against no-prescription peptide sources, especially for injectable products 1, 8.
Risks for competitive athletes
Athletes have an extra risk: eligibility. WADA’s prohibited list includes many substances that can affect performance or recovery pathways, and BPC-157 is described in the sports-medicine literature as banned by some professional and collegiate sports bodies 1, 6.
Is BPC-157 hard on the kidneys?
BPC-157 is reported to be cleared by the kidneys, but kidney clearance does not prove kidney safety. Patients with kidney disease should not assume any peptide is safe without a clinician’s review 1.
What the supplied evidence says about clearance
The supplied review reports that BPC-157 is metabolized in the liver, has a half-life of less than 30 minutes, and is cleared by the kidneys. These are pharmacology details, not proof that daily use is safe for human kidneys 1.
Why kidney safety is not established in humans
To establish kidney safety, human studies would need to track kidney function, dose exposure, duration, other medications, hydration status, and baseline kidney disease. Those data are not established for BPC-157 in the supplied evidence 1.
When patients should ask a licensed clinician before using any peptide
Patients should speak with a licensed clinician before using any peptide if they have kidney disease, liver disease, immune conditions, cancer history, pregnancy, breastfeeding, infection risk, bleeding risk, or multiple medications. This is not because every peptide is dangerous; it is because individual risk matters 7.
Does Chia offer BPC-157?
Chia does not list BPC-157 as a current treatment. We provide education on investigational peptides because patients ask us about them, but we do not present BPC-157 as something Chia sells or prescribes.
Chia does not list BPC-157 as a current treatment
Our current catalog includes clinician-reviewed options such as GHK-Cu cream, NAD+ injection or nasal spray, sermorelin, and glutathione injection or nasal spray. BPC-157 is not listed in our current treatment catalog.
How Chia approaches peptide education and clinician-reviewed prescribing
At Chia, care starts online with a health questionnaire reviewed by a licensed US provider. When clinically appropriate, treatments in our catalog are compounded by state-licensed US 503A pharmacies and shipped to the patient’s door. Dosing is provider-guided and adjusted over time; a prescription is never guaranteed.
Why investigational or non-approved peptides require extra caution
Investigational peptides require extra caution because online demand can grow before human evidence, labeling, dosing, and safety data are ready. For BPC-157, the honest answer is that the science is early, human data are limited, and product quality matters 1, 8.
How should patients think about BPC-157 claims online?
BPC-157 claims online should be checked against study type, human evidence, and regulatory status. A personal story can be sincere and still not prove that the peptide caused the result.
Separate testimonials from clinical evidence
Testimonials do not control for placebo effects, natural healing, rehab, sleep, nutrition, other injections, or time. Clinical trials are designed to reduce those biases, and BPC-157 does not yet have the level of human trial evidence needed for strong claims 1.
Check whether studies are human, animal, or cell-based
When you see a claim, ask: was this shown in people, animals, or cells? For BPC-157, the evidence base is mostly preclinical, so claims about human tendon healing, knee pain, gut repair, or daily safety should be treated as unproven 1.
Avoid assuming a peptide is safe because it is popular
Popularity is not safety data. If a peptide is injected, bought without a prescription, or sourced from a “research chemical” seller, the quality and sterility concerns become part of the medical risk 8.
What peptides stack well with BPC-157?
BPC-157 is commonly discussed with other repair or longevity peptides, but combination use has even less human evidence than single-peptide use. These pairings should be understood as research or clinical-practice discussions, not recommended protocols 1.
BPC-157 and TB-500
BPC-157 and TB-500 are commonly combined in clinical and research practice for tissue-repair discussions because both are discussed around soft-tissue healing pathways. The safety caveat is important: combination-specific human trials are lacking, and overlapping injection and product-quality risks may compound uncertainty 1.
BPC-157 and GHK-Cu
BPC-157 and GHK-Cu are discussed together in skin and wound-repair contexts because both are tied to tissue remodeling pathways. Chia offers GHK-Cu cream, but we do not offer BPC-157; combination claims should not be treated as proven human outcomes 1.
BPC-157 and sermorelin
BPC-157 and sermorelin are sometimes discussed together because BPC-157 research includes growth-hormone receptor expression, while sermorelin acts through the growth-hormone axis. Chia offers sermorelin, but there are no established BPC-157 plus sermorelin human protocols or outcome data 1.
Frequently asked questions
There is no established daily-use safety profile and no evidence-based human dose in the supplied evidence. Daily use should not be started based on online protocols or social media claims 1.
No. BPC-157 and TB-500 are different peptides. They are both discussed in tissue-repair contexts, but they have different origins, proposed mechanisms, and regulatory questions 1.
Chia does not list BPC-157 as a current treatment and does not present it as something we prescribe. For any peptide or prescription treatment, patients should use licensed medical care rather than no-prescription research-chemical sources 8.
The bottom line: BPC-157 is an interesting investigational peptide with mostly preclinical evidence and major human-data gaps. If you are dealing with pain, injury recovery, gut symptoms, or performance pressure, the safer next step is not a research-peptide vendor. It is a licensed clinician who can help you weigh evidence, risk, and appropriate care.
References
- 1.Caldwell JM, Paziuk T, Kerzner B, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine. 2025.
- 2.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Materials, July 23-24, 2026. FDA. 2026.
- 3.Drug Topics. PCAC recommends six peptides for 503A Bulks List inclusion, including BPC-157, TB-500, MOTS-c, Semax, and Epitalon. Drug Topics. 2026.
- 4.U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs database. FDA. 2026.
- 5.U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA. 2026.
- 6.World Anti-Doping Agency. The 2026 Prohibited List: International Standard. WADA. 2026.
- 7.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA. 2026.
- 8.U.S. Food and Drug Administration. BeSafeRx: Know Your Online Pharmacy. FDA. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
